# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Reiterated 2024 Financial OutlookThe Company continues to expect full year 2024 total sepsis product revenue of $10.0 million t...
T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(2.66) per share which missed the analyst consensus estimate of $(2.2...
Canaccord Genuity analyst Kyle Mikson maintains T2 Biosystems (NASDAQ:TTOO) with a Hold and lowers the price target from $12...
https://t.co/156OpGGCCy https://t.co/SCcZwLnY0d